The Cushing's Syndrome Diagnostic and Treatment Market is projected to expand from USD 0.40 billion in 2025 to USD 0.56 billion by 2030, reflecting a Compound Annual Growth Rate (CAGR) of 6.9%.
Cushing’s syndrome is characterized by prolonged exposure to elevated levels of cortisol (the stress hormone).
This condition often results from the improper functioning of the pituitary glands, which secrete adrenocorticotropic hormone (ACTH). ACTH, in turn, stimulates the adrenal glands (located atop the kidneys) to produce cortisol.
Key symptoms include weight gain, distinct pink or purple stretch marks, fragile skin prone to bruising, and occasionally, the development of type 2 diabetes. Treatment modalities encompass reducing corticosteroid use, surgical intervention, and pharmacological therapies.
The market growth forecast is underpinned by a global increase in Cushing's syndrome cases.
In the United States, the American Association of Neurological Surgeons estimates an annual incidence of 10-15 cases per million individuals.
Pituitary adenomas, a primary etiology of Cushing's disease, contribute to over 70% of adult cases and approximately 60% of cases in adolescents and children.
European Union data indicates a worldwide prevalence rate for endogenous Cushing's syndrome of approximately 1 in 26,000. Within the EU, the yearly incidence is 1 in 1,400,000, with peak incidence observed between 25 and 40 years of age.
These epidemiological factors are expected to drive market expansion.
The competitive landscape is characterized by continuous innovation in diagnostic and therapeutic solutions.
Growing incidence rates for Cushing's syndrome are stimulating increased investment from pharmaceutical and medical device firms globally.
In March 2020, the U.S. Food and Drug Administration (FDA) approved Isturisa oral tablets for adults with Cushing's disease who have persistent disease post-surgery or are ineligible for pituitary gland surgery. This approval for Novartis followed a study involving 137 adult patients, yielding positive clinical outcomes.
March 2021 saw PGI doctors introduce Ga-68 CRH PET-CT, a novel technique designed to precisely locate pituitary gland tumors, a primary cause of Cushing's syndrome. This diagnostic advancement is expected to enhance treatment strategies.
In May 2021, Sparrow Pharmaceuticals initiated a Phase 2 clinical trial for SPI-62, an investigational HSD-1 inhibitor. This study assesses the efficacy and safety of the lead small molecule in Cushing's syndrome patients presenting with hyperlipidemia, impaired glucose tolerance, or type 2 diabetes. The trial was scheduled to commence later in 2021.
The FDA accepted a novel drug application (NDA) for a steroidogenesis inhibitor for endogenous Cushing's syndrome in May 2021. Strongbridge Biopharma acknowledged the FDA's acceptance and filing of its Recorlav NDA, signaling potential advancements in pharmacological treatment options.
Surgical intervention is anticipated to command a substantial share of the market.
Treatment approaches for Cushing's syndrome are diverse. Surgical procedures are a prevalent choice globally, particularly for tumor-induced cases where complete surgical removal is recommended.
Hospitals are allocating considerable resources to refine surgical techniques and adopt advanced equipment. For example, Apollo Hospitals Enterprise Ltd. in India provides surgical options, reflecting broader investment trends in healthcare infrastructure.
The expansion of e-Health and online healthcare platforms is also expected to influence market dynamics.
Novartis
Corcept Therapeutics Inc.
StrongBridge Biopharma
Orphagen Pharmaceuticals Inc.
HRA Pharma
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 0.40 billion |
| Total Market Size in 2030 | USD 0.56 billion |
| Forecast Unit | Billion |
| Growth Rate | 6.9% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Diagnostic Test, Treatment, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|